Answers are grounded in this paper and cite their sources.
Patent review demonstrates superior efficiency of nanoparticle delivery over conventional ophthalmic formulations, indicating strong potential to overcome existing ocular treatment barriers.
Nanotechnology has evolved in a big way in the area of nanodrug delivery. The present paper focuses on scientific basis, methods and applications of available nanoparticles and nanodrugs for ocular drug delivery. Nanotechnology has opened the vistas of cheaper, economical, easy deliverables to meet challenges of conventional ocular drug delivery in past. Still today, science of nanotechnology in ophthalmic use is in its infancy. In last decade, FDA approved only 21 conventional ocular drugs while 30 new nondrugs were approved since the year 1995. It is today a matter of eye-catching attention that the recently proved efficiency of nanoparticles for ocular drug delivery is far better than old conventional drug delivery systems in terms of dose, stability, cell targeting, particle size etc. The present paper puts evidence as patent review on the nanoparticles for ocular delivery methods related to drug entrapment, method of manufacturing, toxicity and drug regulatory control
No takes yet. Share an insight, caveat, or question.
Rakesh Sharma (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: